• Synereca Pharmaceuticals

  Led · Equity · Aug 2015

  Synereca develops novel compounds intended to restore and enhance the activity of existing antibiotics against drug-resistant Gram-negative bacteria. Preclinical results have shown that combining the company’s compounds with current antibiotics can restore and enhance activity against resistant pathogens that cause difficult-to-treat infections. The company intends to use newly raised funds to develop these compounds to address bacterial resistance to current antibiotics. Synereca is led by CEO Clayton Duncan and is a portfolio company of Accele Biopharma. It maintains laboratories in Oklahoma City and North Carolina. To date the company has received $2.5m in funding. Synereca Pharmaceutics is a research-stage biopharmaceutical company developing novel orally active drugs to restore or increase the effectiveness of existing antibiotics. Its programs focus on potentiating antibiotics against drug-resistant Gram-negative bacteria. The company has two lead research programs: compounds that potentiate Colistin without enhancing toxicity, and inhibitors of RecA, a key bacterial DNA repair enzyme involved in resistance development and transmission. Synereca intends to use the recent financing to advance these research programs. The company raised $1.4M in convertible debt financing to support these efforts. Synereca is based in Oklahoma City, OK, and is led by Clayton Duncan as acting CEO.

• Otologic Pharmaceutics

  Led · Series A · Apr 2014

  Otologic Pharmaceutics is a development-stage biopharmaceutical company based in Oklahoma City focused on developing and commercializing novel pharmacological approaches to treat hearing disorders. Its lead product candidate is referenced as NHPN-1010, and the article also identifies HPN1010 as an oral treatment for Acute Hearing Loss. The company plans to advance its lead candidate into clinical development, with HPN1010 scheduled to enter clinical trials in 2014. Otologic intends to use the proceeds from its recent financing to advance development of NHPN-1010. The company underwent executive leadership change in conjunction with the financing: Clayton I. Duncan of Accele Biopharma was named CEO, replacing David Karlman. No operating metrics (revenue/users) were disclosed in the article. Otologic Pharmaceutics is a development-stage pharmaceutical company based in Oklahoma City focused on commercializing novel pharmacological solutions for hearing health. Its core work centers on advancing therapeutics for inner ear disorders and other hearing-health applications. The company has in-licensed a portfolio of 19 patents that underpin its programs. A team of nationally and internationally recognized inner ear medicine experts, biomedical research scientists and business leaders supports its development and commercialization efforts. Otologic recently closed a financing round of undisclosed amount led by the OCAST Technology Business Finance Program with participation from INTEGRIS Health and the Oklahoma Medical Foundation. The company says the funding will enable it to advance its therapeutics and continue building the business.

No current team members are available.